Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Immutep - Trading Halt (ASX:IMM)

To view the announcement, download the attached PDF.

Immutep - Charles River Laboratories to run IMP761 Toxicology Study (ASX:IMM)

Appointment of Charles River Laboratories ("Charles River") to run Immutep’s preclinical toxicology study evaluating the safety and toxicity of IMP761 Form...read more

Immutep - Publication of Abstracts for ASCO 2023 Annual Meeting (ASX:IMM)

New data published from Part C of TACTI-002 Phase II Trial evaluating eftilagimod alpha plus pembrolizumab in metastatic 2nd line head and neck squamous cell carcinoma Dee...read more

Immutep - 1st patient dosed in AIPAC-003 ph2/3 breast cancer trial (ASX:IMM)

SYDNEY, AUSTRALIA – 25 May 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developi...read more

Immutep - Promising New Data in 1st line NSCLC from INSIGHT-003 Trial (ASX:IMM)

Efti plus standard-of-care anti-PD-1 therapy and doublet chemotherapy in 1st line non-small cell lung cancer is well tolerated and continues to show promising initial signals of...read more

Immutep - Excellent initial Overall Survival Benefit in 1st line NSCLC (ASX:IMM)

Immuno-oncology combination of eftilagimod alpha (efti) and the leading anti-PD-1 therapy generates meaningful long-term survival in non-small cell lung cancer patients in Phase...read more

Immutep - FDA supportive of Efti registrational trial in lung cancer (ASX:IMM)

SYDNEY, AUSTRALIA – 16 May 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing nov...read more

Immutep - Change of Director's Interest Notice - R Howard (ASX:IMM)

To view the notice, download the attached PDF.

Immutep - Approval to start Efti & Bavencio trial in urothelial cancer (ASX:IMM)

Investigator-initiated study jointly funded with Merck KGaA, Darmstadt, Germany, will evaluate dual immuno-oncology (IO) combination of eftilagimod alpha and BAVENCIO®...read more

Immutep Quarterly Activities Report and Appendix 4C (ASX:IMM)

Initiation of integrated Phase II/III AIPAC-003 trial evaluating eftilagimod alpha (efti) and paclitaxel in HER2-neg/low metastatic breast cancer and triple-negative breast cancer ...read more

Immutep to announce new TACTI-002 data at ASCO 2023 (ASX:IMM)

Final results from Part C of the Phase II TACTI-002 trial in 2nd line head and neck squamous cell carcinoma patients to be presented SYDNEY, AUSTRALIA – 27 April 2023 – Immutep L...read more

Immutep appoints Dr Florian Vogl as Chief Medical Officer (ASX:IMM)

SYDNEY, AUSTRALIA – 26 April 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune...read more

Immutep - Response to ASX Aware Query (ASX:IMM)

By email only Dear Mr Zhao, Immutep Limited – Response to Query Letter I refer to your letter dated 5 April 2023 in relation to the ASX Query Letter. Immutep Limited ...read more

Immutep - Initiation of Phase 2 Trial for Efti in Soft Tissue Sarcoma (ASX:IMM)

Soft tissue sarcoma, an orphan disease, represents a high unmet medical need with a poor prognosis First time efti will be studied in neoadjuvant, non-metastatic cancer setting...read more

Notification of cessation of securities - IMM (ASX:IMM)

To view the notification, download the attached PDF.

Viewing: 91 - 105 of 200 Previous | Next